Kristine M Wylie1, George M Weinstock2, Gregory A Storch3. 1. The Department of Pediatrics The Genome Institute, Washington University School of Medicine, St. Louis, Missouri. 2. The Genome Institute, Washington University School of Medicine, St. Louis, Missouri. 3. The Department of Pediatrics.
Abstract
BACKGROUND: We observed an increase in the number of rotavirus cases in the St. Louis area during the 2012-2013 rotavirus season compared with recent seasons. We aimed to determine whether the rotavirus cases during the 2012-2013 rotavirus season were of types not included in licensed vaccines. METHODS: Microbiology laboratories of 3 children's hospitals in St. Louis provided samples that were positive using rapid antigen tests from 2010 to 2013. The majority of samples were from St. Louis Children's Hospital. We determined rotavirus genotypes by polymerase chain reaction tests and further characterized a subset of viruses by genome sequencing and comparative sequence analysis. RESULTS: Eighty-six percent (24 of 28) of typed viruses analyzed from the 2012-2013 rotavirus season were G12. We performed whole genome sequencing on 8 G12 viruses, all of which were VP4 type P[8]. The sequenced viruses showed differences from vaccine strains in major antigenic epitopes on the VP7 protein, but most epitopes on VP4 were conserved. Rotavirus vaccine histories were available for 11 G12 cases, of whom 10 had not been vaccinated. CONCLUSIONS: G12 was a dominant community-wide genotype in 2013. Most of the G12 cases for whom vaccine histories were available had not received rotavirus vaccine. The experience demonstrates the potential for rapid shifts in rotavirus genotype distribution and underscores the need for vigilant surveillance to detect unusual genotypes that might escape from vaccine protection.
BACKGROUND: We observed an increase in the number of rotavirus cases in the St. Louis area during the 2012-2013 rotavirus season compared with recent seasons. We aimed to determine whether the rotavirus cases during the 2012-2013 rotavirus season were of types not included in licensed vaccines. METHODS: Microbiology laboratories of 3 children's hospitals in St. Louis provided samples that were positive using rapid antigen tests from 2010 to 2013. The majority of samples were from St. Louis Children's Hospital. We determined rotavirus genotypes by polymerase chain reaction tests and further characterized a subset of viruses by genome sequencing and comparative sequence analysis. RESULTS: Eighty-six percent (24 of 28) of typed viruses analyzed from the 2012-2013 rotavirus season were G12. We performed whole genome sequencing on 8 G12 viruses, all of which were VP4 type P[8]. The sequenced viruses showed differences from vaccine strains in major antigenic epitopes on the VP7 protein, but most epitopes on VP4 were conserved. Rotavirus vaccine histories were available for 11 G12 cases, of whom 10 had not been vaccinated. CONCLUSIONS: G12 was a dominant community-wide genotype in 2013. Most of the G12 cases for whom vaccine histories were available had not received rotavirus vaccine. The experience demonstrates the potential for rapid shifts in rotavirus genotype distribution and underscores the need for vigilant surveillance to detect unusual genotypes that might escape from vaccine protection.
Authors: D D Griffin; T Nakagomi; Y Hoshino; O Nakagomi; C D Kirkwood; U D Parashar; R I Glass; J R Gentsch Journal: Virology Date: 2002-03-15 Impact factor: 3.616
Authors: Guillermo M Ruiz-Palacios; Irene Pérez-Schael; F Raúl Velázquez; Hector Abate; Thomas Breuer; SueAnn Costa Clemens; Brigitte Cheuvart; Felix Espinoza; Paul Gillard; Bruce L Innis; Yolanda Cervantes; Alexandre C Linhares; Pío López; Mercedes Macías-Parra; Eduardo Ortega-Barría; Vesta Richardson; Doris Maribel Rivera-Medina; Luis Rivera; Belén Salinas; Noris Pavía-Ruz; Jorge Salmerón; Ricardo Rüttimann; Juan Carlos Tinoco; Pilar Rubio; Ernesto Nuñez; M Lourdes Guerrero; Juan Pablo Yarzábal; Silvia Damaso; Nadia Tornieporth; Xavier Sáez-Llorens; Rodrigo F Vergara; Timo Vesikari; Alain Bouckenooghe; Ralf Clemens; Béatrice De Vos; Miguel O'Ryan Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Timo Vesikari; David O Matson; Penelope Dennehy; Pierre Van Damme; Mathuram Santosham; Zoe Rodriguez; Michael J Dallas; Joseph F Heyse; Michelle G Goveia; Steven B Black; Henry R Shinefield; Celia D C Christie; Samuli Ylitalo; Robbin F Itzler; Michele L Coia; Matthew T Onorato; Ben A Adeyi; Gary S Marshall; Leif Gothefors; Dirk Campens; Aino Karvonen; James P Watt; Katherine L O'Brien; Mark J DiNubile; H Fred Clark; John W Boslego; Paul A Offit; Penny M Heaton Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Brian Rha; Jacqueline E Tate; Daniel C Payne; Margaret M Cortese; Benjamin A Lopman; Aaron T Curns; Umesh D Parashar Journal: Expert Rev Vaccines Date: 2014-01-06 Impact factor: 5.217
Authors: Daniel J DiStefano; Nikolai Kraiouchkine; Laura Mallette; Marianne Maliga; Gregory Kulnis; Paul M Keller; H Fred Clark; Alan R Shaw Journal: J Clin Microbiol Date: 2005-12 Impact factor: 5.948
Authors: Valentine N Ndze; Hajnalka Papp; Eric A Achidi; Kamga H Gonsu; Brigitta László; Szilvia Farkas; Péter Kisfali; Béla Melegh; Mathew D Esona; Michael D Bowen; K Bányai; Jon R Gentsch; Abena M T Odama Journal: J Med Virol Date: 2013-08 Impact factor: 2.327
Authors: Slavica Mijatovic-Rustempasic; Elizabeth N Teel; Tara K Kerin; Jennifer J Hull; Sunando Roy; Geoffrey A Weinberg; Daniel C Payne; Umesh D Parashar; Jon R Gentsch; Michael D Bowen Journal: Infect Genet Evol Date: 2013-11-21 Impact factor: 3.342